Surrozen, Inc./DE Comprehensive Income
Surrozen, Inc./DE (SRZN) reported Comprehensive Income of -$63.56 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2025-03-31
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$28.04M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was -$1.43M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$25.26M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$8.83M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$63.56M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$42.80M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$36.13M.
- Surrozen, Inc./DE comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$54.77M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$28.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$29.47M derived: sum of 2 quarters · filed 2025-03-31 | -$54.73M derived: sum of 3 quarters · filed 2025-03-31 | -$63.56M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$1.43M 10-Q · filed 2024-11-06 | -$26.70M derived: sum of 2 quarters · filed 2024-11-06 | -$35.52M 10-Q · filed 2024-11-06 | -$44.44M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$25.26M 10-Q · filed 2024-08-12 | -$34.09M 10-Q · filed 2024-08-12 | -$43.01M derived: sum of 3 quarters · filed 2025-03-31 | -$53.45M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$8.83M 10-Q · filed 2024-05-08 | -$17.74M derived: sum of 2 quarters · filed 2025-03-31 | -$28.19M derived: sum of 3 quarters · filed 2025-03-31 | -$37.52M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$19.36M derived: sum of 2 quarters · filed 2025-03-31 | -$28.70M derived: sum of 3 quarters · filed 2025-03-31 | -$42.80M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$10.45M 10-Q · filed 2024-11-06 | -$19.78M derived: sum of 2 quarters · filed 2024-11-06 | -$33.89M 10-Q · filed 2024-11-06 | -$34.48M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$9.33M 10-Q · filed 2024-08-12 | -$23.44M 10-Q · filed 2024-08-12 | -$24.03M derived: sum of 3 quarters · filed 2024-08-12 | -$37.34M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$14.11M 10-Q · filed 2024-05-08 | -$14.70M derived: sum of 2 quarters · filed 2024-05-08 | -$28.00M derived: sum of 3 quarters · filed 2024-05-08 | -$41.98M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$592.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$13.90M derived: sum of 2 quarters · filed 2024-04-10 | -$27.87M derived: sum of 3 quarters · filed 2024-04-10 | -$36.13M 10-K · filed 2024-04-10 |
| 2022-09-30 | -$13.30M 10-Q · filed 2023-11-08 | -$27.28M derived: sum of 2 quarters · filed 2023-11-08 | -$35.53M 10-Q · filed 2023-11-08 | -$50.59M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$13.97M 10-Q · filed 2023-08-09 | -$22.23M 10-Q · filed 2023-08-09 | -$37.29M derived: sum of 3 quarters · filed 2023-08-09 | -$51.32M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$8.26M 10-Q · filed 2023-05-10 | -$23.31M derived: sum of 2 quarters · filed 2023-05-10 | -$37.35M derived: sum of 3 quarters · filed 2023-05-10 | -$50.00M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$15.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$29.09M derived: sum of 2 quarters · filed 2023-03-31 | -$41.74M derived: sum of 3 quarters · filed 2023-03-31 | -$54.77M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$14.04M 10-Q · filed 2022-11-14 | -$26.69M derived: sum of 2 quarters · filed 2022-11-14 | -$39.71M 10-Q · filed 2022-11-14 | -$50.54M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$12.65M 10-Q · filed 2022-08-11 | -$25.68M 10-Q · filed 2022-08-11 | -$36.50M derived: sum of 3 quarters · filed 2022-08-11 | -$45.14M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$13.02M 10-Q · filed 2022-05-11 | -$23.85M derived: sum of 2 quarters · filed 2022-05-11 | -$32.48M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$19.46M derived: sum of 2 quarters · filed 2022-03-28 | -$32.72M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$8.63M 10-Q · filed 2021-11-15 | -$21.89M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |